It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The following is a summary of “Plasma Lipopolysaccharide-Binding Protein (LBP) Is Induced in Critically Ill Females with Gram ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Nine species (240 strains) of gram-negative bacilli were studied; 221 were freshly isolated from the urinary and intestinal tracts, wounds and abscesses. Thirteen strains of salmonella and 6 of ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.